Atara's Q2 Loss Widens as Cash Drops to $9.9M; Going Concern Warning Reiterated
ATRA has more than doubled off its 52-week low of $3.92.
Summary
A widening Q2 loss and dwindling cash reserves reinforce the going concern risk, with only $9.9M on hand and a workforce cut to 10 employees.
Key Events · Earnings and Guidance · ATRA
-
Q2 Net Loss of $4.8M
The quarter produced a net loss of $4.8M, compared with net income of $2.4M in Q2 2025; the six-month loss reached $9.0M versus income of $40.4M a year earlier.
-
Cash Runway Below 12 Months
Cash, cash equivalents and short-term investments totaled $9.9M as of June 30, 2026, insufficient to fund operations for at least 12 months; the going concern warning was reiterated.
-
Workforce Cut to 10 Employees
A June 2026 reduction in force eliminated approximately 23% of the workforce, leaving about 10 employees; $0.8M in severance costs were recognized.
-
ATM Sales Continue
Under the 2023 ATM facility, 991,017 shares were sold at an average price of $7.97 for gross proceeds of $7.9M; $79.3M remains available.
Analysis · ATRA · Life Sciences
The second quarter swung to a net loss of $4.8 million, reversing a year-ago profit, while cash and investments dwindled to just $9.9 million — not enough to fund operations for 12 months. The going concern warning was reiterated, and a June reduction in force cut 23% of staff to about 10 employees. Continued ATM sales and a warrant issuance tied to a debt amendment underscore the urgent need for capital.
At the time of this filing, ATRA was trading at $9.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $83.1M. The 52-week trading range was $3.92 to $19.15. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.